PATENT CLAIM ANALYSIS

Application Number: 15755797
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-11
Patent Classification: ["514", "235800"]

Abstract:
The present disclosure pertains to a pharmaceutical combination comprising (a) an alpha-isoform specific PI3K inhibitor, (b) an MDM2 inhibitor, and optionally (c) a BCL-2 inhibitor; combined preparations and pharmaceutical compositions thereof; the uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer a subject in need thereof comprising administering a therapeutically effective amount of such combination.

Claim (Index 48):
The pharmaceutical combination according to  claim 43  or  46 , wherein the combination is for simultaneous or sequential administration.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 88.0
- Lexical Diversity: 1.61702
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15755122', '15755140', '13799076', '15861555', '14429367']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7956452502272381
- 35 USC 102 Novelty (BERT): 0.5309459321482121
- Combined Prediction Score: 0.7691753184193355
- Mean Citation Score: 292.86425
- Max Citation Score: 317.25934
- Similarity Product: 153.12373028735104

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test